Our preclinical results indicate that chemotherapeutic agents directed against LCH, when used at high doses, decreased Mcl-1 expression and killed Mo-DCs from patients, without affecting BCL2A1 expression. The gene discussed is BCL2A1; the disease is Langerhans cell histiocytosis.